PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
Phase 1 Terminated
21 enrolled
(VELA) Study of BLU-222 in Advanced Solid Tumors
Phase 1 Terminated
50 enrolled
Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
Phase 1 Terminated
88 enrolled 18 charts
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Phase 1 Terminated
10 enrolled
Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers
Phase 1 Terminated
58 enrolled
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
23 enrolled
Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors
Phase 1 Terminated
44 enrolled
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Phase 1 Terminated
88 enrolled
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
Phase 1 Terminated
19 enrolled
AM-003
Phase 1 Terminated
5 enrolled
Lithium
Phase 1 Terminated
2 enrolled
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Phase 1 Terminated
133 enrolled
A Study of SGN-ALPV in Advanced Solid Tumors
Phase 1 Terminated
43 enrolled
A Study of SGN-STNV in Advanced Solid Tumors
Phase 1 Terminated
111 enrolled
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
Phase 1 Terminated
79 enrolled 42 charts
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
115 enrolled
CAR
Phase 1 Terminated
9 enrolled
PDL1x41BB
Phase 1 Terminated
160 enrolled
Intraperitoneal Docetaxel in Combination With mFOLFOX6 for Gastric Cancer Patients With Peritoneal Carcinomatosis
Phase 1 Terminated
2 enrolled
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
Phase 1 Terminated
78 enrolled 39 charts
TORCH
Phase 1 Terminated
10 enrolled
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
Phase 1 Terminated
14 enrolled 20 charts
A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005
Phase 1 Terminated
11 enrolled 10 charts
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Phase 1 Terminated
16 enrolled
A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
Phase 1 Terminated
60 enrolled
A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer
Phase 1 Terminated
39 enrolled
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
Phase 1 Terminated
1 enrolled
A Safety Study of SGN-CD47M in Patients With Solid Tumors
Phase 1 Terminated
16 enrolled
A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression
Phase 1 Terminated
9 enrolled
Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
Phase 1 Terminated
6 enrolled
A Study of SC-007 in Subjects With Advanced Cancer
Phase 1 Terminated
7 enrolled
Gastric In Vivo Study
Phase 1 Terminated
8 enrolled
Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer
Phase 1 Terminated
23 enrolled
Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer
Phase 1 Terminated
3 enrolled
S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer
Phase 1 Terminated
14 enrolled
Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors
Phase 1 Terminated
54 enrolled
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
Phase 1 Terminated
16 enrolled
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
Phase 1 Terminated
60 enrolled
A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.
Phase 1 Terminated
47 enrolled
Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer
Phase 1 Terminated
14 enrolled
Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors
Phase 1 Terminated
24 enrolled